Abcam & Research-Use Antibodies: Customer Perspective II

Former VP, Biology at CyVek

Why is this interview interesting?

  • Buying research use antibodies from Abcam vs R&D Systems
  • Perspectives on the opportunity for Abcam in proteomics
  • Comparison of RUA vendor pricing strategies
  • Demand outlook for research use antibodies
Print

Executive Bio

Former VP, Biology

Former VP, Biology at CyVek

This executive has a background in nucleic acid amplification, next-generation DNA sequencing, microfluidics, genetics, molecular biology and product development, with experience in innovative technology development from the initial start-up to product launch stage. He is currently the SVP R&D at IsoPlexis, and previously held senior roles 4Catalyzer and Quantum-Si and Qiagen among others. At Qiagen he was Head of the global Next Generation Sequencing (NGS) development team, responsible for management of the technology development driving QIAGEN’s NGS GeneReader system. Read more

View Profile Page

Interview Transcript

... (transcript preview, sign up to read more) ...

Sign up to read the full interview and hundreds more.

Partner Interview

Interviews hosted by one of our investor partners are only available in text format.

Did you like this article ?